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lateral sclerosis: a phase 1, randomised, ﬁ rst-in-man study
Timothy M Miller, Alan Pestronk, William David, Jeﬀ rey Rothstein, Ericka Simpson, Stanley H Appel, Patricia L Andres,  Katy Mahoney, 
Peggy Allred, Katie Alexander, Lyle W Ostrow, David Schoenfeld, Eric A Macklin, Daniel A Norris, Georgios Manousakis, Matthew Crisp, 
Richard Smith, C Frank Bennett, Kathie M Bishop, Merit E Cudkowicz
Summary 
Background Mutations in SOD1 cause 13% of familial amyotrophic lateral sclerosis. In the SOD1 Gly93Ala rat model 
of amyotrophic lateral sclerosis, the antisense oligonucleotide ISIS 333611 delivered to CSF decreased SOD1 mRNA 
and protein concentrations in spinal cord tissue and prolonged survival. We aimed to assess the safety, tolerability, 
and pharmacokinetics of ISIS 333611 after intrathecal administration in patients with SOD1-related familial 
amyotrophic lateral sclerosis.  
Methods In this randomised, placebo-controlled, phase 1 trial, we delivered ISIS 333611 by intrathecal infusion using 
an external pump over 11·5 h at increasing doses (0·15 mg, 0·50 mg, 1·50 mg, 3·00 mg) to four cohorts of eight patients 
with SOD1-positive amyotrophic lateral sclerosis (six patients assigned to ISIS 333611, two to placebo in each cohort). 
We did the randomisation with a web-based system, assigning patients in blocks of four. Patients and investigators 
were masked to treatment assignment. Participants were allowed to re-enrol in subsequent cohorts. Our primary 
objective was to assess the safety and tolerability of ISIS 333611. Assessments were done during infusion and over 
28 days after infusion. This study was registered with Clinicaltrials.gov, number NCT01041222. 
Findings Seven of eight (88%) patients in the placebo group versus 20 of 24 (83%) in the ISIS 333611 group had 
adverse events. The most common events were post-lumbar puncture syndrome (3/8 [38%] vs 8/24 [33%]), back pain 
(4/8 [50%] vs 4/24 [17%]), and nausea (0/8 [0%] vs 3/24 [13%]). We recorded no dose-limiting toxic eﬀ ects or any safety 
or tolerability concerns related to ISIS 333611. No serious adverse events occurred in patients given ISIS 333611. 
Re-enrolment and re-treatment were also well tolerated. 
Interpretation This trial is the ﬁ rst clinical study of intrathecal delivery of an antisense oligonucleotide. ISIS 333611 
was well tolerated when administered as an intrathecal infusion. Antisense oligonucleotides delivered to the CNS 
might be a feasible treatment for neurological disorders. 
Funding The ALS Association, Muscular Dystrophy Association, Isis Pharmaceuticals.
Introduction
Our knowledge of the genetic basis of many 
neurodegenerative diseases has progressed greatly in the 
past 20 years. Causative mutations have been identiﬁ ed 
for Huntington’s disease, spinal muscular atrophy, spinal 
and bulbar muscular atrophy, Alzheimer’s disease, 
Parkinson’s disease, and amyotrophic lateral sclerosis.1 
The challenge now is to turn this knowledge into eﬀ ective 
treatments. For dominantly inherited disorders in which 
a mutant protein becomes toxic, reducing the 
concentration of the protein is a potential approach and 
antisense oligonucleotides are one means of doing so.2 
Antisense oligonucleotides are short, synthetic nucleic 
acids that have been chemically modiﬁ ed to increase 
their stability in biological ﬂ uids and their potency in 
binding their mRNA target.  One mechanism by which 
antisense oligonucleotides function is by binding to a 
speciﬁ c target mRNA through Watson-Crick base-pairing 
and causing degradation of the mRNA by activation of 
the nuclear enzyme RNase H.3 Because antisense 
oligonucleotides do not cross the blood–brain barrier,4 
they must be delivered directly to the CNS to treat 
neurodegenerative diseases. One possible approach is to 
administer them intrathecally into the CSF, which results 
in widespread delivery to the CNS.4–6 
Genetic changes in more than ten genes are known to 
cause familial amyotrophic lateral sclerosis, an adult-
onset neurodegenerative disease characterised by loss or 
dysfunction of both upper and lower motor neuron 
pathways7 and in some cases dementia. Mutations in 
SOD1 account for roughly 2% of all cases of amyotrophic 
lateral sclerosis. Although such mutations were identiﬁ ed 
almost 20 years ago, no treatments exist that substantially 
slow either the sporadic or SOD1-linked forms of 
amyotrophic lateral sclerosis. Diﬀ erent SOD1 mutations 
are associated with diﬀ erent ages of onset and rates of 
progression, and nearly all are inherited dominantly.8 
The toxicity of SOD1 is the result of a gain of toxic 
function rather than a loss of enzymatic function; thus, 
reducing concentrations of the mutant protein 
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is predicted to slow progression of SOD1-linked 
amyotrophic lateral sclerosis.7 Evidence of the usefulness 
of antisense oligonucleotides for treatment of 
neurodegenerative diseases includes: (1) widespread 
distribution of antisense oligonucleotides throughout 
the CNS after CSF administration;4–6 (2) reduction of 
SOD1 mRNA and protein in the brain and spinal cord 
tissues;4 and (3) increased survival after direct delivery to 
the CSF in an SOD1 Gly93Ala animal model of 
amyotrophic lateral sclerosis.4 The drug used in these 
studies was ISIS 333611, an antisense oligonucleotide 
that reduces expression of wild-type and mutant human 
SOD1 protein in transgenic rats and in cultured human 
cells.4,9 
We aimed to assess the safety, tolerability, and 
pharmacokinetics of a single dose of ISIS 333611 in 
patients with SOD1 familial amyotrophic lateral sclerosis. 
This is the ﬁ rst clinical study to test the eﬀ ects of 
delivering an antisense oligonucleotide directly into 
human CSF as a treatment for a widespread disorder of 
the CNS.
Methods
Study design and participants
We did this placebo-controlled, double-blind, randomised, 
dose escalation phase 1 study at four centres in the USA 
(Washington University in St Louis, St Louis, MO; 
Massachusetts General Hospital, Boston, MA; Johns 
Hopkins University, Baltimore, MD; and Methodist 
Neurological Institute, Houston, TX). Patients were 
eligible if they were aged 18 years or older, had a 
documented mutation in SOD1, showed clinical signs of 
weakness attributed to amyotrophic lateral sclerosis, had 
a forced vital capacity of more than 50% of their predicted 
value, were not using invasive respiratory support, and 
were medically able to undergo insertion of a temporary 
intrathecal catheter. We used a 50% cutoﬀ  for forced vital 
capacity because patients with amyotrophic lateral 
sclerosis who have a forced vital capacity of more than 
50% have fewer complications with minor procedures.10 
Participants who were taking riluzole had to have been on 
a stable dose for at least 30 days before the start of the 
study and had to stay on that dose throughout the study. 
Patients were ineligible if they had been treated with an 
investigational drug for amyotrophic lateral sclerosis 
within 30 days or within a period of ﬁ ve-times the half-life 
of the drug before screening, had clinically signiﬁ cant 
abnormalities in laboratory test results (including 
coagulation measures), or had a medical condition that 
would interfere with the study.
The institutional review boards of the participating 
study centres approved the study and we did the trial in 
accordance with the Declaration of Helsinki and the 
International Conference on Harmonisation Good 
Clinical Practice guidelines. All participants provided 
written informed consent. A data safety and monitoring 
board monitored the trial. 
Randomisation and masking
Participants were enrolled sequentially in four cohorts of 
escalating single doses of ISIS 333611 (0·15 mg, 0·50 mg, 
1·50 mg, 3·00 mg). Within each cohort, patients were 
randomly assigned to ISIS 333611 or placebo in a ratio of 
3:1. An approved protocol amendment made after 
completion of treatment of the ﬁ rst dose cohort allowed 
participants to re-enrol in a diﬀ erent cohort if more than 
60 days had elapsed since they were treated previously and 
they still qualiﬁ ed for the study. Re-enrolled patients were 
re-assigned without regard to previous assignment. After 
participants were deemed eligible for the study (provided 
informed consent and met all inclusion criteria), they 
were sequentially allocated unique patient identiﬁ cation 
numbers and assigned to a treatment group. 
We generated the randomisation sequence with 
WebEZ, an independent, centralised, web-based 
randomisation system (Almac Clinical Services, 
Souderton, PA, USA). We randomly assigned patients in 
blocks of four sequential participants. Randomisation 
codes were accessed by the site pharmacist. Study drug 
or placebo was labelled only with the patient identiﬁ cation 
number before delivery to the study staﬀ . Patients, 
caregivers, investigators (including other staﬀ  at 
participating institutions), and Isis Pharmaceuticals 
personnel were masked to treatment allocation 
throughout the study. Treatment assignment was known 
only by the pharmacist at each site, the data safety and 
monitoring board, and a central biostatistician who 
provided statistical support to the data safety and 
monitoring board. No events required premature 
unmasking of patient allocation or study data. 
Procedures
ISIS 333611 (provided in sterile, unpreserved, buﬀ ered 
saline solution at 20 mg/mL, pH=7·4) and the placebo 
plus diluents  (sterile, phosphate-buﬀ ered saline) were 
provided by Isis Pharmaceuticals. ISIS 333611 was 
diluted to the appropriate concentration for each dose 
and used within 24 h of preparation. The study drug was 
given as one intrathecal infusion. ISIS 333611 or placebo 
(0·25 mL) was infused intrathecally for 11 h 22 min with a 
CADD-MS 3 syringe-based ambulatory infusion pump 
(Smiths Medical MD, St Paul, MN, USA) equipped with 
a 3 mL Medication Cartridge via a Codman FlexTip Plus 
intraspinal catheter. The infusion time was chosen to 
slowly deliver the exact volume within the programming 
features of the pump. We chose this volume and timing 
to provide roughly half a day of dosing, assuming 
chronic, continuous infusion of 0·5 mL per day in future 
clinical trials. The tip of the intrathecal catheter was 
placed under ﬂ uoroscopic guidance near the T8–T10 
spinal level by a lumbar puncture using a 17G Tuohy 
needle inserted into the L3/L4 space, although the 
protocol allowed placement at a diﬀ erent level if patient 
anatomy or clinical judgment dictated. We took a CSF 
sample via the catheter placement needle before infusion 
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to analyse pharmacokinetics and SOD1 protein 
concentrations. At the end of the infusion, the catheter 
was immediately removed and another CSF sample 
taken by a separate lumbar puncture one segment above 
or below the catheter placement site. We measured ISIS 
333611 concentrations in plasma 13 times from before 
infusion to 12 h after infusion.
Autopsy was not included in the protocol, but through 
a separate existing protocol we obtained  spinal cord 
tissue samples from a SOD1 Ala4Val patient who was 
enrolled in cohorts 3 and 4 and who died from 
amyotrophic lateral sclerosis-related causes 3 months 
after the study. These samples enabled us to directly 
assess drug and SOD1 concentrations in this patient. 
We analysed ISIS 333611 concentration in spinal cord 
tissue samples taken at autopsy from the cervical, 
thoracic, and lumbar regions. We measured SOD1 
concentration in CSF and spinal cord tissue (100–200 mg 
samples of frozen cervical and lumbar spinal cord) by a 
validated, commercially available human SOD1 ELISA 
(eBioscience BMS222MST). The SOD1 protein 
concentration is the mean of four independent ELISA 
assays for CSF and three independent assays for spinal 
cord tissue. For comparison, we measured SOD1 
concentrations in cervical and lumbar spinal cord from 
autopsy tissue collected at Washington University and 
Johns Hopkins University (USA) from six patients not 
included in this trial (three with SOD1 familial 
amyotrophic lateral sclerosis and three with sporadic 
amyotrophic lateral sclerosis).
Safety assessments were: recording adverse events, 
physical and neurological examinations, recording vital 
signs, clinical laboratory tests (haematology, clinical 
chemistry, complement, coagulation), electrocardiograms 
(ECGs), assessment of amyotrophic lateral sclerosis 
functional rating scale revised score, forced vital capacity, 
and recording use of concomitant medications. Based on 
preclinical ﬁ ndings of high exposure to the drug, we 
monitored for signs of cerebellar dysfunction. Safety 
assessments were done on day 1 before and after infusion, 
day 2, day 8, and day 29. Patients were also assessed by a 
telephone call on day 15. Safety information was reviewed 
by the data safety and monitoring board after day 8 for the 
last member of each cohort, to provide a dose escalation 
recommendation. 
We collected data on CSF SOD1 concentration as a 
pharmacodynamic biomarker in all participants, 
including after re-enrolment. We estimated ISIS 333611 
concentrations by a modiﬁ cation of the hybridisation 
ELISA method.11 The method was validated for human 
plasma and CSF in accordance with current standard 
practice for immunobinding assays by PPD Bioanalytical 
(Wilmington, NC, USA). Stability of ISIS 333611 in a 
frozen matrix (up to 3 months) and up to ﬁ ve freeze-thaw 
cycles was also conﬁ rmed. 
Our primary objective was to assess the safety and 
tolerability of ISIS 333611 given as a single intrathecal 
infusion in patients with SOD1 familial amyotrophic 
lateral sclerosis.  Secondary objectives were to assess CSF 
and plasma pharmacokinetics after intrathecal delivery.
Sex Age 
(years)
Family history of 
amyotrophic lateral 
sclerosis
SOD1 mutation Age at onset 
(years)
Site of onset
1 Female 49 Yes Glu49Lys 47 Limb
2 Male 59 Yes Ala4Val 59 Limb
3 Female 36 Yes Gly37Arg 23 Limb
4 Male 41 Yes Ala4Thr 41 Limb
5 Male 47 Yes Leu38Val 45 Limb
6 Male 51 Yes Ile113Thr 47 Limb
7 Female 50 Yes Ala4Val 50 Limb
8 Female 58 Yes Ala4Val 58 Limb
9 Male 63 Yes Gly85Arg 63 Limb
10 Male 52 Yes Ala4Val 51 Limb
11 Male 48 Yes Asn139Lys 45 Limb
12 Male 54 Yes Ile113Thr 48 Limb
13 Male 44 No Ala89Val 42 Limb
14 Female 56 Yes Ile113Thr 43 Limb
15 Male 55 Yes Gly93Ser 45 Limb
16 Male 46 Yes Ala4Val 46 Bulbar
17 Male 22 Yes Gly41Ser 22 Limb
18 Male 56 Yes Asp90Ala 55 Limb
19 Male 51 Yes Leu8Val 43 Limb
20 Female 38 Yes Gly93Ala 37 Limb
21 Female 49 Yes Gln22Leu 45 Limb
Table 1: Demographic and clinical characteristics of each participant
Figure 1: Trial proﬁ le
FVC=forced vital capacity. *Not treated because of failed placement of intrathecal catheter. 
26 patients assessed for eligibility
22 enrolled
21 treated 1 not treated*
4 excluded
 3 did not meet inclusion criteria
  2 elevated liver function tests
  1 FVC below minimum
 1 withdrew consent
8 in cohort 1
6 given ISIS 333611
2 given placebo
8 in cohort 2
6 given ISIS 333611
2 given placebo
 (2 re-enrolled from 
 previous cohort)
8 in cohort 3
6 given ISIS 333611
2 given placebo
 (2 re-enrolled from 
 previous cohort)
8 in cohort 4
6 given ISIS 333611
2 given placebo
 (7 re-enrolled from 
 previous cohort)
8 analysed 8 analysed 8 analysed 8 analysed
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Statistical analysis
We estimated a sample size of six patients treated with 
study drug and two treated with placebo per cohort on 
the basis of previous phase 1 single-dose studies of 
antisense oligonucleotides to ensure that the safety and 
tolerability of ISIS 333611 would be adequately assessed 
while minimising unnecessary patient exposure. We did 
not do a statistical test of the number of patients needed. 
We predicted CSF concentrations of ISIS 333611 on the 
basis of CSF volume scaling and CSF drug concentrations 
measured in preclinical studies of Rhesus monkeys. 
We did not do a statistical test to compare predicted 
and measured CSF concentrations of ISIS 333611. 
All patients who received treatment were included 
in the safety, tolerability, and pharmacokinetic 
assessments. All data summaries and pharmacokinetic 
analyses were done with Phoenix WinNonlin 
(version 6.2). This study was registered with Clinicaltrials.
gov, number NCT01041222.
Role of the funding source
The sponsors were involved in the design of the study, 
data collection, data analysis, data interpretation, and 
writing of the report. All authors had full access to the 
trial data and are responsible for the accuracy of the data 
and interpretation of the results. The corresponding 
author had ﬁ nal responsibility for the decision to submit 
for publication. 
Results
We enrolled 22 participants between March, 2010, and 
December, 2011, 21 of whom received treatment 
(ﬁ gure 1). Seven patients enrolled twice, and two 
patients enrolled three times. All treated participants 
completed the study. Participants had various SOD1 
mutations (the most common was SOD1 Ala4Val) with 
associated variability in age at disease onset and time 
since diagnosis (table 1). Demographic and disease 
characteristics were much the same between groups, 
except for the proportion of men (table 2). 
27 patients (84%) reported adverse events (table 3). The 
most common adverse events were post-lumbar puncture 
syndrome and back pain, which in all cases were judged 
to be related to the infusion procedure and not to the 
study drug. No adverse events were deemed related to 
treatment. The most common adverse events did not 
diﬀ er between ISIS 333611 and placebo groups, and the 
number of adverse events did not increase with increasing 
dose of ISIS 333611. Two serious adverse events (lacunar 
infarction and pneumonia, both requiring admission to 
hospital) were reported, both in the same placebo-treated 
patient. In the participants that received ISIS 333611 in 
more than one cohort, the number of adverse events 
decreased with re-enrolment (table 4). 
We recorded no changes related to study drug for vital 
signs, neurological or physical examinations, haema-
tological assessments, clinical chemistry, coagulation 
measures, complement, urinalysis, or ECGs (data not 
shown). All participants had a slight, not clinically 
signiﬁ cant decrease in haematological test results on 
day 2 that recovered by day 29, probably caused by mild 
haemodilution secondary to increased hydration in an 
attempt to prevent post-lumbar puncture syndromes 
(data not shown). Consistent with reports12,13 of nystagmus 
in some patients with amyotrophic lateral sclerosis, ﬁ ve 
participants (two in the placebo group and three in the 
ISIS 333611 group) had nystagmus or abnormal eye 
movements during the study. One of the participants 
treated with ISIS 333611 had these signs before treatment. 
Generally, these abnormalities were intermittent, only 
evident on neurological examination, not clinically 
signiﬁ cant, and not clearly related to treatment with ISIS 
333611 or lumbar puncture. 
Placebo group (n=8) ISIS 333611 group (n=24)
Mean age (range; years) 52 (38–63) 50 (22–64)
Men (%) 3 (38%) 19 (79%)
White (%) 8 (100%) 18 (75%)
Mean amyotrophic lateral sclerosis functional rating 
scale, revised score (range)
33 (22–41) 36 (24–44)
Mean forced vital capacity (range) 83% (53–110) 84% (54–113)
Table 2: Patient characteristics by treatment group
First enrolment
(n=21)
Second enrolment
(n=9)
Third enrolment
(n=2)
Post-lumbar puncture syndrome 10 (48%; 12) 1 (11%; 1) 0 (0%; 0)
Back pain 6 (29%; 6) 2 (22%; 2) 0 (0%; 0)
Nausea 3 (14%; 3) 0 (0%; 0) 0 (0%; 0)
Headache 2 (10%; 2) 1 (11%; 1) 0 (0%; 0)
Data are number of patients (%; number of events). Only events that occurred in >7% of patients are included 
(ie, >2 enrolments).
Table 4: Adverse events by enrolment 
Placebo 
group
(n=8)
ISIS 333611 
group
(n=24)
Events in the ISIS 333611 group (n)
Cohort 1 Cohort 2 Cohort 3 Cohort 4
Any serious adverse event 1 (13%; 2) 0 (0%; 0) 0 0 0 0
Any adverse event 7 (88%; 23) 20 (83%; 50) 23 9 7 11
Post-lumbar puncture syndrome 3 (38%; 5) 8 (33%; 8) 4 2 1 1
Back pain 4 (50%; 4) 4 (17%; 4) 2 1 1 0
Nausea 0 (0%; 0) 3 (13%; 3) 2 0 1 0
Vomiting 0 (0%; 0) 2 (8%; 2) 2 0 0 0
Headache 1 (13%; 1) 2 (8%; 2) 0 2 0 0
Fall 0 (0%; 0) 2 (8%; 2) 1 1 0 0
Dizziness 0 (0%; 0) 2 (8%; 2) 1 0 0 1
Data are number of patients (%; number of events) unless otherwise stated. Events listed are those that occurred 
in >5% of ISIS 333611 treated patients (ie, occurred in >1 patient).
Table 3: Adverse events by group and cohort
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The amyotrophic lateral sclerosis functional rating 
scale revised score and forced vital capacity were 
generally stable during the study and did not diﬀ er 
substantially between placebo and ISIS 333611 groups 
(median amyotrophic lateral sclerosis functional rating 
scale revised score absolute change –1·5 vs –0·6; median 
forced vital capacity absolute change –3·0% vs –4·8%). 
After treatment, we detected ISIS 333611 in CSF of all 
participants in the ISIS 333611 group. CSF 
concentrations of ISIS 333611 increased with increasing 
doses (ﬁ gure 2A). The measured con centrations were 
within two to three times of the predicted 
concentrations. Although antisense oligonucleotides do 
not cross the blood–brain barrier when administered 
systemically, they are cleared from CSF into the plasma 
consistent with CSF turnover after intrathecal delivery.4 
In cohorts 1 and 2, plasma drug concentrations were 
generally below the lower limit of quantiﬁ cation of the 
assay (1 ng/mL). In cohorts 3 and 4, plasma drug 
concentrations increased during infusion and then 
rapidly decreased over the next 12 h (ﬁ gure 2B). Table 5 
and the appendix show ISIS 3336111 concentrations in 
plasma (area under the curve0–24) compared with 
predicted concentrations.
We analysed spinal cord tissue samples obtained at 
autopsy from a patient with a SOD1 Ala4Val mutation. 
ISIS 333611 concentrations were 218 ng/g in a lumbar 
spinal cord sample, 122 ng/g in a thoracic spinal cord 
sample, and 39 ng/g in a cervical spinal cord sample. 
These results and the gradient between lumbar and 
cervical samples are consistent with expected tissue 
concentrations based on preclinical studies of Rhesus 
monkeys (predicted concentration vs measured 
concentration: 344 ng/g vs 218 ng/g in the lumbar 
sample, 282 ng/g vs 122 ng/g in the thoracic sample, 
36 ng/g vs 39 in the cervival sample; appendix). The 
CSF concentration of ISIS 333611 at the end of infusion 
for this patient was 3·5 μg/mL during cohort 3 and 
6·3 μg/mL during cohort 4. 
We measured SOD1 protein concentrations in cervical 
and lumbar spinal cord samples from one trial 
participant and six patients who did not take part in the 
trial. In the non-trial patients, SOD1 protein 
concentration ranged from 2141 ng/mL to 4543 ng/mL 
in the cervical cord and from 1494 ng/mL to 3478 ng/mL 
in the lumbar cord. For the treated patient, SOD1 
concentration was 2259 ng/mL in the cervical sample 
and 1867 ng/mL in the lumbar sample. The 
cervical:lumbar ratio of SOD1 concentrations was 1·2:1 
in the trial participant and ranged from 0·9:1 to 1·7:1 
in patients not treated in the study. In our analysis of 
CSF SOD1 concentrations in all participants, as 
expected,9 CSF SOD1 concentration did not change 
substantially in participants enrolled in more than one 
cohort, with most SOD1 CSF concentrations within 
12% of the pretreatment or previous cohort value 
(ﬁ gure 3). 
Figure 2: CSF and plasma concentrations of ISIS 333611
Delivered and measured concentrations in the CSF (A) and plasma concentrations over time (B). Plasma 
concentrations for cohorts 1 and 2 were below the limit of detection of the assay. The CSF draw was unsuccessful 
for one patient in cohort 1 and one patient in cohort 3.
0 1 2 3 4
Delivered intrathecally (mg)
At
 e
nd
 o
f i
nf
us
io
n 
(μ
g/
m
L)
Pl
as
m
a 
co
nc
en
tr
at
io
n 
(n
g/
m
L)
0·1
0 4 8 12 16141062 20 242218
Time (h)
0
1
2
3
4
5
6
7
8
9
10
11
12
B
1
10
100
A
Cohort 1
Cohort 2
Cohort 3
Cohort 4
Predicted cohort 1
Predicted cohort 2
Predicted cohort 3
Predicted cohort 4
Cohort 3
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Dose n Area under the curve (0–24 h; h×ng/mL)
Mean (SE) Median (range) Predicted
1 0·15 mg 6 4·2 (2·9) 0·0 (0·0–19·9) ··
2 0·50 mg 6 0·0 (0·0) 0·0 (0·0–0·0) ··
3 1·50 mg 6 34·9 (10·3) 25·3 (12·3–77·6) 60·9
4 3·00 mg 6 77·6 (26·2) 62·1 (24·8–199·8) 121·7
Area under the curve was calculated from individual measurements of plasma from 
start of treatment to 12 h after treatment. Predicted area under the curve = monkey 
area under the curve at steady state 24 h/(human bodyweight [70 kg]/monkey 
bodyweight [4 kg]) × (human dose [total mg]/monkey dose [mg/day]). The 
appendix shows area under the curve values in Rhesus monkeys. The area under the 
curve value at 0·1 mg per day was used to estimate human values. 
Table 5: Predicted and measured human plasma concentration of ISIS 
333611 by cohort 
See Online for appendix
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Discussion
The ability to directly modulate gene expression in the 
brain and spinal cord aﬀ ords new treatment opportunities 
for neurological diseases, especially neurodegenerative 
disorders. Our ﬁ rst-in-human clinical study shows the 
feasibility of intrathecal delivery of antisense 
oligonucleotides into the CNS. Because this approach is 
new, we used single, escalating, low-dose infusions. ISIS 
333611 was well tolerated with no dose-limiting toxic 
eﬀ ects or safety concerns. The data from this study 
provide encouragement for further development of 
antisense oligonucleotides for the treatment of 
neurodegenerative diseases, although the small numbers 
of participants and low doses limit broader conclusions 
about the tolerability of intrathecal antisense 
oligonucleotides. Direct infusion of an antisense 
oligonucleotide into tumour tissue by convection-
enhanced delivery also seems to be similarly well 
tolerated.14
We report a clear dose-dependent relation between 
drug concentrations in CSF and plasma. The agreement 
between measured pharmacokinetic data and the 
predicted values supports the use of CSF volume and 
bodyweight scaling for prediction of human CSF 
concentration and plasma exposure. These ﬁ ndings 
should help the selection of doses in future clinical 
studies.
Based on an estimated tissue half-life of roughly 
28 days in preclinical studies, the autopsy samples from 
a patient who died from amyotrophic lateral sclerosis 
were taken roughly three half-lives from when the last 
dose was given. Drug concentrations in spinal cord tissue 
were easily measured and were much higher than the 
limit of quantiﬁ cation (5 ng/g). Our results suggest that 
the human elimination half-life might be in the same 
range as that in monkeys (roughly 30 days). 
In patients who participated in more than one cohort 
and therefore for whom repeat CSF samples were 
available, SOD1 CSF concentrations were on average 
within 12% of the original value. This ﬁ nding is 
consistent with the low dose of antisense oligonucleotides 
used and is also consistent with previous repeated 
measurements of SOD1 CSF concentration,9 showing an 
average 7% variation in SOD1 CSF protein concentration 
when measured 1–12 months apart. The stability of CSF 
SOD1 concentrations shown by these data, coupled with 
data from studies of rats,9 showing that reduction of 
SOD1 concentrations in brain tissue correlates with 
reduced SOD1 in the CSF, strongly support use of CSF 
SOD1 protein concentrations as a pharmacodynamic 
marker for antisense oligonucleotide activity in future 
clinical trials of SOD1 amyotrophic lateral sclerosis. 
 Our study has several limitations. The doses we used 
were intended to represent a single dose that would be 
given as a continuous infusion and thus were low. We 
predict that the highest dose in our study would need to 
be given continuously for 4 days to reduce SOD1 mRNA 
and protein concentrations in human spinal cord. The 
small number of participants also limits conclusions 
about safety because very rare events might not occur in 
a small sample. Lastly, the ISIS 333611 group had more 
men than did the placebo group. Nevertheless, our study 
is an important ﬁ rst step in using antisense 
oligonucleotides to treat neurological disease (panel). 
Patients with Ala4Val mutations in SOD1 typically 
progress from symptom onset to death very rapidly (ie, 
in less than 12 months) and thus even short-term 
reduction of SOD1 concentrations might be beneﬁ cial. 
Before testing long-term treatment in more slowly 
progressive SOD1-related amyotrophic lateral sclerosis 
or treating patients before they develop symptoms, we 
should more fully understand the eﬀ ects of chronic, 
long-term reductions of SOD1 concentrations, because 
knockout of SOD1 has been linked to liver cancer15 and 
late life motor neuropathy.16 Our approach mitigates 
these concerns because of the only partial reduction of 
SOD1 concentration and little exposure to peripheral 
tissues after intrathecal delivery. The antisense 
oligonucleotide we used is designed to activate RNase H 
mediated degradation of all SOD1, rather than a 
particular SOD1 mutant, which enables this approach to 
be applied broadly to almost all of the more than 100 
diﬀ erent mutations in SOD1 known to cause 
amyotrophic lateral sclerosis.7 Experiments in mice 
show that wild-type SOD1 can increase the toxicity of 
mutant SOD1;17 thus decreasing both mutant and wild-
type SOD1 has an additional theoretical beneﬁ t. 
Studies suggest that SOD1 could also be involved in 
sporadic amyotrophic lateral sclerosis. First, Gruzman 
and colleagues18 reported an SOD1-reactive protein 
(after chemical crosslinking of homogenates of spinal 
Figure 3: SOD1 protein concentrations in CSF of patients enrolled in more than one cohort
Measured by ELISA. SOD1 mutation and cohort number are shown for each patient. *Placebo group for that 
cohort. 
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cord tissues) in a small number of patients with sporadic 
amyotrophic lateral sclerosis but not controls. Second, 
antibodies that target misfolded SOD1 showed 
misfolded SOD1 in vulnerable spinal cord neurons of 
some patients with amyotrophic lateral sclerosis, but 
not control patients19,20 while other well designed, larger 
studies21 did not ﬁ nd this pathology in sporadic 
amyotrophic lateral sclerosis. Third, reduction of SOD1 
concentrations in astrocytes derived from patients with 
sporadic amyotrophic lateral sclerosis reversed the toxic 
eﬀ ects of these astrocytes when cocultured with motor 
neurons,22 again implying that SOD1 might contribute 
to the pathogenesis of sporadic amyotrophic lateral 
sclerosis. Although the rationale for treatment with 
antisense oligonucleotides is strongest for familial 
SOD1-related amyotrophic lateral sclerosis, this 
therapeutic approach could be considered for treatment 
of sporadic amyotrophic lateral sclerosis, should 
suﬃ  cient data emerge. Our study will enable future 
studies of similar antisense drugs for familial SOD1 
amyotrophic lateral sclerosis, other genetic forms of 
amyotrophic lateral sclerosis, and other neuro-
degenerative diseases. 
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